Skip to main content
OpenTrials
Completed

NCT Number: NCT00773006

Canadian Anticoagulant Percutaneous Coronary Intervention Registry

Advances in mechanical intervention (PCI) and anticoagulation therapy have been the cornerstone of treatment of patients with coronary artery disease. However, the large diversity of approaches to anticoagulation during PCI introduces gaps in knowledge regarding management of cardiac patients. As such, we have initiated a national PCI registry to elucidate anticoagulant choice, dosing strategies, case selection dynamics, and clinical outcomes in the Canadian health care environment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Coronary Artery Disease Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Alberta

Edmonton, Alberta, T6G 2B7, Canada

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 or more years of age.
  • Undergoing PCI during treatment with LMWH
  • Provision of written and informed consent

Exclusion criteria

  • Language, medical, or psychiatric barriers that preclude understanding of informed consent process.
  • Patients in which the site investigator is unable to comply with completion of study documentation following PCI, i.e. patients with planned transfer to another hospital not participating in the registry.
  • Enrollment in a clinical trial involving another anticoagulant agent.

Treatment and study plan

Primary outcomes

  1. Description of anticoagulant management during PCI and current practices of participating centres will be undertaken

    Time frame: in-hospital

Secondary outcomes

  1. In-hospital safety outcomes including - major, minor bleeding, requirement for transfusion, death, myocardial infarction (or re-MI), myocardial ischemia requiring urgent revascularization, and major bleeding

    Time frame: in-hospital

  2. In-hospital angiographic complications: no reflow, thrombus, occlusion of collateral branches, distal embolism, coronary dissection, acute closure of the culprit vessel

    Time frame: in-hospital

  3. PCI-related resources utilization during the study period, including cost of PCI and its treatment (e.g. duration of hospital stay, drug costs, costs related to bleeding such as transfusions)

    Time frame: in-hospital

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Registry information

Official study title

Canadian Prospective, Observational Study on the Use of LMWH in the Setting of Percutaneous Coronary Intervention

Acronym: CAPCIR

Important dates

Study start
2008
Primary completion
2010
Study completion
2011
First posted
Oct 16, 2008
Registry last updated
Oct 5, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.